

Mistakes in therapeutic drug monitoring of biologics in IBD and how to avoid them

Adam Cheifetz

Mistakes In Articles

IBD

June 22, 2023

Therapeutic drug monitoring of biologics in inflammatory bowel disease can address primary non-response and secondary loss of response, which affect up to one-third and half of patients respectively.

KEY POINTS

- Up to one-third of IBD patients are primary non-responders to biological therapy, and up to half lose response over time due to pharmacodynamic failure, pharmacokinetic issues, or immunogenicity with anti-drug antibodies.
- Reactive therapeutic drug monitoring measures drug concentrations and anti-drug antibody levels when primary non-response or secondary loss of response occurs to help explain and manage these outcomes.
- Proactive therapeutic drug monitoring involves routinely measuring drug concentrations and antibodies to achieve and maintain targeted therapeutic levels.
- The material addresses common mistakes and errors to avoid when using therapeutic drug monitoring of biologics in IBD patients, based on available evidence and clinical experience.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflifx.eu/search/d/03dc5e2c-0eb0-11ee-aeec-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.